Data highlights the ability of GPR65 inhibition to bring about a robust Type I/II interferon (IFN) gene signature and reduce tumor burden…
M:M News
Grey Wolf Therapeutics to Present Preclinical Data on First-in-Class ERAP1 Inhibitors at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
New Data Highlight the Potential of Neoantigen-Generating ERAP1 Inhibitors to Drive a Differentiated T Cell Response, Leading to Tumor Growth Inhibition. Proprietary…
Pathios Therapeutics and Sygnature Discovery sign a strategic and innovative partnership
Pathios Therapeutics and Sygnature Discovery sign a strategic and innovative partnership to develop first in class therapies in autoimmune disease and immuno-oncology
Grey Wolf Therapeutics completes £10 million ($14 million) series A financing
Grey Wolf Therapeutics completes £10 million ($14 million) series A financing with Andera Partners and Canaan to fund development of immuno-oncology therapies…